


### New use of PDGFRbeta inhibitors for treatment of T-cell lymphomas

#### BACKGROUND

The major clinical challenge in treating NPM-ALK+ anaplastic large cell lymphomas (ALCL) is its high rate of relapse. Researchers of the Medical University of Vienna identified high expression of PDGFR $\beta$  in the NPM-ALK induced ALCL. Pharmaceutical targeting of PDGFRB using a tyrosine kinase inhibitor (TKI) strongly reduced tumor size in SCID-mice xenografted with NPM-ALK mouse tumor cells, and increased the survival of NPM-ALK+ transgenic mice by more than 90%. These data provide evidence for the use of FDA approved tyrosine kinase inhibitors for the effective treatment of lymphomas and encourage the development of specific clinical trials.



PET-CT scans before and 10d after initiation of imatinib treatment. Axillary lymph nodes (delineated by white dotted line) were PET-CT negative after treatment. L, lung; H, heart; R, rib cage

#### RESULTS

- Human ALCL patients express high levels of PDGFRB
- PDGFRB is a novel target of AP-1
- Clinical relevance: Complete remission in 2 terminally ill patients who were resistant to other established therapies

#### ADVANTAGE

**Imatinib treatment: less toxic, less side effects, first line therapy**

#### NEXT STEPS

Phase II trial: evaluation of the response rate / efficacy to various doses of TKI administered orally in relapsed/refractory patients with ALCL and other PDGFR $\beta$  expressing peripheral T-cell lymphomas (PTCLs), to demonstrate clinical proof of concept.

- Mouse xenograft models
- Mouse NPM-ALK transgenic models

#### FURTHER READING

Nat Med. 2012 Nov;18(11):1699-704;  
Front Biosci (Schol Ed). 2015 Jun 1;7:226-35

**REFERENCE:**  
245.09

#### AVAILABLE FOR:

- development partnership
- license agreement
- patent sale or other

#### APPLICATIONS:

- Treatment of lymphomas
- Solid tumors

#### IPR:

US2012252736 granted

#### CONTACT:

**Claudia Ballaun**

Medical University of Vienna  
Spitalgasse 23, 1090 Vienna  
+43-1-40160 25203  
claudia.ernst-ballaun@  
meduniwien.ac.at  
www.meduniwien.ac.at